OrthoSpin Receives FDA Regulatory Clearance

MISGAV, IsraelSept. 18, 2019 /PRNewswire/ — OrthoSpin Ltd. a portfolio company of The Trendlines Group Ltd. (“Trendlines”) (SGX: 42T) (OTCQX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its smart, robotic external fixation system for orthopedic treatments.

Today, the use of external fixation is a common treatment option for orthopedic-related problems: bone lengthening, setting complex fractures, and correcting deformities. The two main challenges associated with these systems are (1) patient compliance and (2) lack of real-time feedback for the physician. External fixation requires the patient to make multiple manual adjustments every day. This requires significant patient training and involvement and can lead to errors. Many times, the patient does not fully or precisely comply with the mechanical adjustments, which results in less than optimal clinical outcomes.

OrthoSpin’s external fixation system addresses the two major challenges of today’s manual fixation systems. The smart OrthoSpin system automatically makes pre-programmed adjustments, precisely, and continuously, eliminating manual adjustments and patient training. The OrthoSpin external fixation system delivers a better patient experience and it reduces the need for time-consuming follow-ups.

OrthoSpin CEO Oren Cohen remarked, “Receiving FDA clearance is an exciting achievement for us. We were thrilled at the efficient, fast process. Our robotic struts eliminate the need for manual adjustment, improve patient compliance and the process is expected to be less painful. OrthoSpin’s system can monitor biomechanical parameters, and in the future will enable the device to automatically send real-time updates to physicians for following patient progress. This allows fine-tuning of the treatment regimen, if necessary, including a personalized treatment plan for each patient.”

Todd Dollinger, Chairman and CEO, The Trendlines Group added: “OrthoSpin’s achievement makes us very proud. We look forward to continuing to participate in their progress in improving orthopedic treatment and outcomes.”

About OrthoSpin 

OrthoSpin was founded in December 2014 at Trendlines Incubators Israel and operates in the framework of the Incubator Incentive Program of the Israel Innovation Authority. OrthoSpin offers a new robotic treatment system for use in orthopedics, specifically external fixation. OrthoSpin’s innovative system has the potential to change the outcomes of various orthopedic treatments, such as bone lengthening, setting complex fractures, and correcting deformities. In 2018, OrthoSpin completed an investment round led by Johnson & Johnson Innovation – JJDC, Inc.

Contact:

Oren Cohen, CEO
OrthoSpin
+972-54-334-2651
oren@orthospin.com

SOURCE OrthoSpin

Web Site: https://www.trendlines.com/

About Peter Coffaro 474 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 25 years of progressive management success within the medical device industry. Recognized by the World Journal of Orthopedics, Exponential Healthtech, and MedReps.com as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager, Distributor, and Vice President. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy, and Stryker. He is also the founder of OrthoFeed: a popular blog that covers digital orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing, and professional education. Peter holds a B.S. degree in Biology and Chemistry from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.